HC Wainwright Issues Negative Forecast for Alumis Earnings

Alumis Inc. (NASDAQ:ALMS) – Research analysts at HC Wainwright cut their Q1 2025 earnings estimates for shares of Alumis in a note issued to investors on Thursday, March 20th. HC Wainwright analyst M. Kapoor now expects that the company will post earnings per share of ($1.29) for the quarter, down from their prior estimate of ($0.99). HC Wainwright currently has a “Buy” rating and a $15.00 price target on the stock. The consensus estimate for Alumis’ current full-year earnings is ($8.51) per share. HC Wainwright also issued estimates for Alumis’ Q2 2025 earnings at ($1.00) EPS, Q3 2025 earnings at ($1.01) EPS, Q4 2025 earnings at ($1.01) EPS and FY2025 earnings at ($4.26) EPS.

Other equities analysts also recently issued research reports about the company. Cantor Fitzgerald reissued an “overweight” rating on shares of Alumis in a research report on Thursday, March 20th. Oppenheimer began coverage on shares of Alumis in a research report on Thursday, January 30th. They set an “outperform” rating and a $32.00 price objective on the stock. Seven analysts have rated the stock with a buy rating and two have issued a strong buy rating to the stock. According to data from MarketBeat.com, Alumis presently has an average rating of “Buy” and an average price target of $26.00.

Alumis Stock Performance

Shares of ALMS stock opened at $4.00 on Monday. Alumis has a 1 year low of $3.18 and a 1 year high of $13.53. The stock’s 50 day simple moving average is $5.55 and its two-hundred day simple moving average is $8.43.

Institutional Trading of Alumis

Hedge funds and other institutional investors have recently bought and sold shares of the business. Foresite Capital Management V LLC grew its holdings in shares of Alumis by 3.5% in the fourth quarter. Foresite Capital Management V LLC now owns 5,779,348 shares of the company’s stock worth $45,426,000 after purchasing an additional 194,459 shares during the last quarter. Foresite Capital Management VI LLC purchased a new stake in Alumis in the 4th quarter valued at about $33,033,000. Samsara BioCapital LLC purchased a new stake in Alumis in the 3rd quarter valued at about $34,886,000. Tang Capital Management LLC grew its stake in Alumis by 40.6% in the 4th quarter. Tang Capital Management LLC now owns 600,000 shares of the company’s stock worth $4,716,000 after acquiring an additional 173,406 shares in the last quarter. Finally, Ally Bridge Group NY LLC raised its stake in shares of Alumis by 6.4% during the fourth quarter. Ally Bridge Group NY LLC now owns 445,259 shares of the company’s stock valued at $3,500,000 after acquiring an additional 26,843 shares in the last quarter.

About Alumis

Our mission is to significantly improve the lives of patients by replacing broad immunosuppression with targeted therapies. Our name, Alumis, captures our mission to enlighten immunology, and is inspired by the words “allumer”-French for illuminate-and “immunis”-Latin for the immune system. We are a clinical stage biopharmaceutical company with an initial focus on developing our two Tyrosine Kinase 2 (TYK2) inhibitors: ESK-001, a second-generation inhibitor that we are developing to maximize target inhibition and optimize tolerability, and A-005, a central nervous system (CNS) penetrant molecule.